Adaptive Biotechnologies (ADPT) EBITDA Yield: History & Chart

Adaptive Biotechnologies Corporation(ADPT)

Biotechnology · Seattle, WA

$27.57-2.27 (-7.61%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confirming past COVID-19 infections, Adaptive provides T-Detect COVID. Additionally, clonoSEQ functions as a critical clinical diagnostic tool, enabling the detection and continuous monitoring of minimal residual disease in individuals with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia; it is also available as a CLIA-validated laboratory-developed test for other lymphoid cancers. Another specialized offering, immunoSEQ T-MAP COVID, aids vaccine developers and researchers in quantifying T-cell immune responses to vaccines. Beyond its current product lineup, Adaptive Biotechnologies actively develops a pipeline of clinical products and services designed for the diagnosis, monitoring, and treatment of conditions such as cancer, autoimmune disorders, and infectious diseases. Its solutions cater to life science research, clinical diagnostics, and drug discovery applications. The company has established key strategic collaborations: one with Genentech, Inc., for the joint development, manufacturing, and commercialization of neoantigen-directed T-cell therapies aimed at treating various cancers; and another with Microsoft Corporation, dedicated to creating sophisticated diagnostic tests capable of identifying multiple diseases early from a single blood sample.

Seattle, WA

624 employees

www.adaptivebiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Chad Robins

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Adaptive Biotechnologies Corporation (ADPT)	$4.41B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.38B	11.43%	8.95%	6.39%	6.78%
Heartflow, Inc. Common Stock (HTFL)vs ›	$4.35B	N/A	N/A	N/A	N/A
Edgewise Therapeutics, Inc. (EWTX)vs ›	$4.27B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.59B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.64B	2.88%	2.61%	2.07%	1.96%
LivaNova PLC (LIVN)vs ›	$4.14B	6.15%	6.89%	5.07%	4.64%
BillionToOne, Inc. (BLLN)vs ›	$4.71B	1.29%	0.79%	0.79%	0.79%
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.72B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.82B	N/A	0.05%	0.05%	0.05%

NAME

MARKET CAP

EBITDA YIELD

TTM

Adaptive Biotechnologies Corporation (ADPT)

$4.41B

N/A

Indivior Pharmaceuticals Inc (INDV)vs ›

$4.38B

11.43%

8.95%

6.39%

6.78%

Heartflow, Inc. Common Stock (HTFL)vs ›

$4.35B

N/A

Edgewise Therapeutics, Inc. (EWTX)vs ›

$4.27B

N/A

Definium Therapeutics, Inc. (DFTX)vs ›

$4.59B

N/A

LifeStance Health Group, Inc. (LFST)vs ›

$4.64B

2.88%

2.61%

2.07%

1.96%

LivaNova PLC (LIVN)vs ›

$4.14B

6.15%

6.89%

5.07%

4.64%

BillionToOne, Inc. (BLLN)vs ›

$4.71B

1.29%

0.79%

Dianthus Therapeutics, Inc. (DNTH)vs ›

$4.72B

N/A

Mirum Pharmaceuticals, Inc. (MIRM)vs ›

$4.82B

N/A

0.05%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

ADPT EBITDA Yield Metrics

ADPT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics